While PGF can be managed with blood product transfusions or growth factors [Granulocyte colony stimulating factor (G-CSF), thrombopoietin agonists or erythropoietin] [5], this may not be sustainable in the long-term, and is associated with side effects such as iron overload, alloimmunization, thrombosis and bone marrow fibrosis. Here, CSF3 is linked to primary myelofibrosis.